Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Lenalidomide in R/R DLBCL
NCT04436107Phase 1Completed
- Sponsor
- BeiGene
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by BeiGene. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Sep 2020; status: completed.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04436107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436107.